

Grifols creates the Board of Directors' Strategy Committee

- This new Committee will serve the Board of Directors in an advisory capacity on key strategic decisions and will support Management in planning for long-term growth.
- It will be made up of non-executive directors with in-depth knowledge and experience in the plasma industry.
- The Committee will be chaired by the company's non-executive chairwoman and independent director, Ms. Anne-Catherine Berner, proprietary directors Mr. Raimon Grifols Roura and Mr. Víctor Grifols Deu, external director Mr. Tomás Dagá Gelabert, and independent director Mr. Íñigo Sánchez-Asiaín Mardones.
- It will strengthen Grifols' commitment to long-term vision and a rigorous governance model aligned with global best practices.

Barcelona, Spain, September 29, 2025 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leader in plasma-derived medicines, today announced the creation of a Strategy Committee within its Board of Directors. The new committee will ensure that the Board maintains a long-term perspective whilst supporting Management's continued execution of its medium-term Capital Markets Day Plan and thereby safeguarding Grifols' successful track record of strategic growth over the past few decades and positioning the company to sustain success in the future.

The Strategy Committee will provide a framework for shaping Grifols' strategic policies, aligning Management with the long-term interests of shareholders and shareholder value creation while supporting Management with critical expertise where needed to continue advancing in the plasma industry.

The new committee will be composed of five non-executive directors with proven expertise in strategy, regulation, and in-depth knowledge of the plasma business on a global scale. It will be chaired by the company's non-executive chair and independent director, Ms. Anne-Catherine Berner, in line with the recommendations of the CNMV's Code of Good Corporate Governance. The new body will also be composed of proprietary directors Raimon Grifols Roura and Víctor Grifols Deu, external director Tomás Dagá Gelabert, and independent director Íñigo Sánchez-Asiaín Mardones. The new committee will thus combine the vision of the independent directors with the long-term approach, deep industry knowledge, and experience of the founding family, providing a balanced perspective that combines stability, innovation, and strategic direction.

International best practice in corporate governance recognizes the value of specialized committees in enhancing the quality of the Board of Directors' strategic analysis. The new Strategy Committee also reinforces compliance with the Spanish Companies Law, which assigns the Board direct responsibility for the company's strategy.

Grifols' current position as a global leader is the result of a consistent long-term vision built on innovation, stability, and profound industry expertise. The creation of the Strategy Committee reflects the company's commitment to sustaining this vision while consolidating a governance model that is rigorous and prepared for the future.

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

+34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909, committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, manufactures, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' growing knowledge of many chronic, rare, and prevalent, sometimes life-threatening diseases drive the company's innovation in both plasma and other biopharmaceuticals to improve quality of life. Grifols focuses on treating diseases in four main therapeutic areas: immunology, infectious diseases, pulmonology, and critical care.

A pioneer in the plasma industry, Grifols continues to expand its network of donation centers, the largest in the world with nearly 400 centers across North America, Europe, Africa, the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to improve safety from donation to transfusion, as well as clinical diagnostic technologies. It provides high-quality biological supplies for life science research, clinical trials, and the manufacture of pharmaceutical and diagnostic products. The company also supplies tools, information, and services that enable hospitals, pharmacies, and healthcare professionals to provide expert medical care efficiently.

Grifols, with more than 23,800 employees in over 30 countries and regions, is committed to a sustainable business model that sets the standard in continuous innovation, quality, safety, and ethical leadership.

The company's Class A shares are listed on the Spanish Stock Exchange, where they form part of the Ibex-35 (MCE:GRF). Grifols' Class B non-voting shares are listed on the Continuous Market (MCE:GRF.P) and on the US NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, visit www.grifols.com.

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the

real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.